Literature DB >> 9124252

Complications of retained nuclear fragments in the anterior chamber after phacoemulsification with posterior chamber lens implant.

G M Bohigian1, S A Wexler.   

Abstract

PURPOSE: We report two cases in which retained nuclear fragments in the anterior chamber after phacoemulsification and posterior chamber lens implant resulted in intraocular complications.
METHODS: Case reports.
RESULTS: In two eyes of two patients, retained nuclear fragments resulted in minimal anterior chamber reaction but substantial corneal edema and reduced visual acuity. Topical anti-inflammatory medications did not alter the postoperative course. Improvement occurred only when the nuclear fragments were surgically removed.
CONCLUSIONS: Retained nuclear fragments in the anterior chamber can cause corneal edema and reduced vision that may be reversed by removing the fragments.

Entities:  

Mesh:

Year:  1997        PMID: 9124252     DOI: 10.1016/s0002-9394(14)70181-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Retained lens fragment in the anterior segment as a cause of recurrent anterioruveitis.

Authors:  Livia Teo; Soon-Phaik Chee
Journal:  Int Ophthalmol       Date:  2008-11-20       Impact factor: 2.031

2.  Medical malpractice claims related to cataract surgery complicated by retained lens fragments (an American Ophthalmological Society thesis).

Authors:  Judy E Kim; Paul Weber; Aniko Szabo
Journal:  Trans Am Ophthalmol Soc       Date:  2012-12

3.  A retained lens fragment induced anterior uveitis and corneal edema 15 years after cataract surgery.

Authors:  Hae Min Kang; Jong Woon Park; Eun Jee Chung
Journal:  Korean J Ophthalmol       Date:  2011-01-17

4.  Late onset corneal decompensation following retained lens fragment in anterior chamber years after uneventful phacoemulsification.

Authors:  Abhay Vasavada; Rinal Pandit; Vandana Nath; Shail Vasavada; Vaishali Vasavada
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.